UCLA researchers report promising therapeutic approach for Alzheimer's disease
For decades, researchers have been trying, without success, to develop drugs that slow or prevent Alzheimer's disease. Now UCLA investigators suggest that these studies have the right target, but are missing the bulls-eye for Alzheimer’s disease. The target Alzheimer’s research is amyloid-beta; however, the UCLA scientists note that the substance is the correct protein to focus on, what is needed is to direct a drug to a very specific location, which they have discovered on that protein. They reported their findings in the January 23 issue of the Journal of Molecular Biology.
The researchers note that Alzheimer’s disease is the most common cause of late-life dementia and is thought to be caused by a protein known as the amyloid-beta protein, or Abeta, which clumps together in the brain, forming plaques that are thought to destroy neurons. This destruction has an early onset; it can presage clinical signs of the disease by up to 20 years. For decades, researchers have been trying, with limited success, to develop drugs that prevent this clumping. Such drugs require a “target,” a structure they can bind to, thereby preventing the toxic actions of Abeta.
UCLA neurology professor David Teplow and colleagues focused on a particular segment of a toxic form of Abeta and discovered a unique hairpin-like structure that facilitates clumping. “Every 68 seconds, someone in this country is diagnosed with Alzheimer’s,” noted senior author Dr. Teplow, the principal investigator of the NIH-sponsored Alzheimer’s Disease Research Center at UCLA. He added, “Alzheimer’s disease is the only one of the top 10 causes of death in America that cannot be prevented, cured or even slowed down once it begins. Most of the drugs that have been developed have either failed or only provide modest improvement of the symptoms. So finding a better pathway for these potential therapeutics is critical.”
Dr. Teplow explained that the Abeta protein is composed of a sequence of amino acids, much like “a pearl necklace composed of 20 different combinations of different colors of pearl.” One form of Abeta, Abeta40, has 40 amino acids, while a second form, Abeta42, has two extra amino acids at one end. Abeta42 has long been thought to be the toxic form of Abeta; however, until now, no one has understood how the simple addition of two amino acids made it so much more toxic then Abeta40. In his lab, Teplow and his colleagues used computer simulations in which they looked at the structure of the Abeta proteins in a virtual world. The researchers first created a virtual Abeta peptide that only contained the last 12 amino acids of the entire 42–amino-acid-long Abeta42 protein. Then, said Teplow, “we just let the molecule move around in a virtual world, letting the laws of physics determine how each atom of the peptide was attracted to or repulsed by other atoms.”
By taking thousands of snapshots of the various molecular structures the peptides created, the investigators determined which structures formed more frequently than others. From those, they then physically created mutant Abeta peptides using chemical synthesis. “We studied these mutant peptides and found that the structure that made ‘Abeta42 Abeta42’ was a hairpin-like turn at the very end of the peptide of the whole Abeta protein,” noted Dr. Teplow. He added that the hairpin turn structure was not previously known in the detail revealed by the researchers, “so we feel our experiments were novel. Our lab is the first to show that it is this specific turn that accounts for the special ability of Abeta42 to aggregate into clumps that we think kills neurons. Abeta40, the Abeta protein with two less amino acids at the end of the protein, did not do the same thing.”
The study authors note that the work of the Teplow laboratory presents what may the most relevant target yet for the development of drugs to fight Alzheimer’s disease.